New Anticancer Agents in Neuroendocrine Tumors

  • Marta Benavent
  • Amparo Sanchez-Gastaldo
  • Rocio Garcia-Carbonero
Chapter
First Online:

Abstract

Neuroendocrine tumors (NETs) are a heterogeneous family of neoplasms of increasing incidence and challenging clinical management. Although generally more indolent than carcinomas, they have a widely variable clinical behavior and are on occasions associated with a very aggressive clinical course. For many decades, available medical options for the systemic treatment of advanced disease have been scant and of limited value in the control of disease progression. In this context, sunitinib and everolimus have triggered great enthusiasm in the field as they have proved for the first time in well-designed controlled clinical trials that there are agents able to improve the clinical outcome of this complex disease. In this chapter, we will review emergent data on new drugs for the treatment of G1–2 NETs, including recently approved angiogenesis and mTOR inhibitors, as well as other novel-targeted agents in perspective.

Keywords

Targeted agents Neuroendocrine Gastroenteropancreatic Therapy Everolimus Sunitinib PI3K HER IGFR HDAC 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Yao JC, Hassan M, Phan A et al (2008) One hundred years after ‘‘carcinoid’’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072PubMedCrossRefGoogle Scholar
  2. 2.
    Garcia-Carbonero R, Capdevila J, Crespo-Herrero G et al (2010) Incidence, patterns of care and prognostic factors for outcome of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21:1794–1803PubMedCrossRefGoogle Scholar
  3. 3.
    Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72PubMedCrossRefGoogle Scholar
  4. 4.
    Oberg K (2009) Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors. Curr Opin Endocrinol Diabetes Obes 16(1):72–78PubMedGoogle Scholar
  5. 5.
    García-Carbonero R, Salazar R, Sevilla I, Isla D (2011) SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). Clin Transl Oncol 13:545–551PubMedCrossRefGoogle Scholar
  6. 6.
    Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027PubMedCrossRefGoogle Scholar
  7. 7.
    Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20(21):4368–4380PubMedCrossRefGoogle Scholar
  8. 8.
    Zhang J, Jia Z, Li Q et al (2007) Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109(8):1478–1486PubMedCrossRefGoogle Scholar
  9. 9.
    Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23(5):939–952PubMedCrossRefGoogle Scholar
  10. 10.
    Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35PubMedCrossRefGoogle Scholar
  11. 11.
    Kulke MH, Lenz HJ, Meropol NJ et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403–3410PubMedCrossRefGoogle Scholar
  12. 12.
    Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513PubMedCrossRefGoogle Scholar
  13. 13.
    Yao JC, Phan A, Hoff PM et al (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b. J Clin Oncol 26:1316–1323PubMedCrossRefGoogle Scholar
  14. 14.
    Yao JC, Phan A, Fogleman D (2010) Randomized runin study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 28(15):4002Google Scholar
  15. 15.
    Mitry E, Walter T, Baudin E et al (2012) Efficacy and safety of bevacizumasb combined with capecitabine in pregressive, metastatic well-differentiated digestive endocrine tumors (BETTER study). J Clin Oncol 30:4071CrossRefGoogle Scholar
  16. 16.
    Hobday TJ, Rubin J, Holen K et al (2007) MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol (Meeting Abstracts) 25(18 suppl):4504Google Scholar
  17. 17.
    Castellano D, Capdevila J, Salazar R et al (2010) Neuroendocrine tumors. Ann Oncol 21(8):850 AbstractGoogle Scholar
  18. 18.
    Phan AT, Yao JC, Fogelman KR et al (2010) A prospective, multi-institucional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 28:15 (suppl; abstr 4001)CrossRefGoogle Scholar
  19. 19.
    Grande E, Castellano D, García-Carbonero R et al. (2012) PAZONET: a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE). ESMO Congress Vienna 2012 (Abstract 2131)Google Scholar
  20. 20.
    Pavel E, Bartel C, Heuck F (2008) Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas. J Clin Oncol 26:(May 20 suppl; abstr 14684)Google Scholar
  21. 21.
    Anthony L, Chester M, Michael S (2008) Phase II open-label clinical trial of vatalanib (PTK787) in patients with progressive neuroendocrine cancer 2008. Gastrointestinal cancers symposium Abstract: 146Google Scholar
  22. 22.
    Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A et al (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406PubMedCrossRefGoogle Scholar
  23. 23.
    Sung M, Kvols L, Wolin E (2008 ) Phase II proof-of-concept study of atiprimod in patients with advanced low-to intermediate-grade neuroendocrine carcinoma. J Clin Oncol 26:(May 20 suppl; abstr 4611)Google Scholar
  24. 24.
    Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW (2002) Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20(18):3772–3784PubMedCrossRefGoogle Scholar
  25. 25.
    Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX et al (2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24:3555–3561PubMedCrossRefGoogle Scholar
  26. 26.
    Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2):128–135PubMedCrossRefGoogle Scholar
  27. 27.
    Jiao Y, Shi C, Edil BH et al (2011) DAXX/ATRX, MEN1 and mTOR pathway genes are frequently altered in pancreatic Neuroendocrine tumors. Science 331(6021):1199–1203PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27(13):2278–2287PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Oberstein PE, Saif MW (2012) Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 6:41–51PubMedCentralPubMedGoogle Scholar
  30. 30.
    Moreno A, Akcakanat A, Munsell MF et al (2008) Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15(1):257–266PubMedCrossRefGoogle Scholar
  31. 31.
    Duran I, Kortmansky J, Singh D et al (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148–1154PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Hobday TJ, Qin R, Reidy DL et al. (2012) Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): results of a planned interim efficacy analysis. J Clin Oncol 30(Suppl):Abstract 4047Google Scholar
  33. 33.
    Yao JC, Phan AT, Chang DZ et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26:4311–4318PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69–76PubMedCrossRefGoogle Scholar
  35. 35.
    Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2102PubMedCrossRefGoogle Scholar
  36. 36.
    Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523PubMedCrossRefGoogle Scholar
  37. 37.
    López-Calderero I, Sánchez Chávez E, García-Carbonero R (2010) The insulin-like growth factor pathway as a target for cancer therapy. Clin Transl Oncol 2(5):326–338CrossRefGoogle Scholar
  38. 38.
    Reidy D, Hollywood E, Segal M (2010) A phase II clinical trial of MK0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). J Clin Oncol 28:15s, (suppl; abstr 4163)Google Scholar
  39. 39.
    Kulke M, Chan JA, Ryan DP et al. (2012) A multi-institutional phase II open-label study of AMG 479 in advanced carcinoid and pancreatic neuroendocrine tumors. J Clin Oncol 30(Suppl):Abstract 4125Google Scholar
  40. 40.
    Anthony L, Loehrer P, Leong S (2010) Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma. J Clin Oncol 28:15s, (suppl; abstr TPS220)Google Scholar
  41. 41.
    Hobday T, Holen K, Donehower R (2006) A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 24:18S (June 20 Supplement, ASCO Annual Meeting Proceedings Part I: 4043)Google Scholar
  42. 42.
    Firdaus I, Shih KC, Zakari A et al. (2012) Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET). J Clin Oncol 30(Suppl):Abstract 2127Google Scholar
  43. 43.
    Shah M, Binkley P, Chan K (2006) Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 12(13):3997–4003PubMedCrossRefGoogle Scholar
  44. 44.
    Rajguru S, Lubner S, Mulkerin D (2012) A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in low-grade neuroendocrine tumors. J Clin Oncol 30:(suppl; abstr e14554)Google Scholar

Copyright information

© Springer-Verlag France 2014

Authors and Affiliations

  • Marta Benavent
    • 1
  • Amparo Sanchez-Gastaldo
    • 1
  • Rocio Garcia-Carbonero
    • 1
  1. 1.Oncology DepartmentHospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) (Universidad de Sevilla, CSIC, HUVR)SevillaSpain

Personalised recommendations